Serum Institute seeks Rs 100 cr in damages from trial subject

Experts feel trust is broken as trial was not halted; Chennai resident had sought Rs 5 cr in compensation

As questions mount on Oxford-AstraZeneca vaccine trials in India after a 40-year-old participant fell sick and sought damages of Rs 5 crore, Serum Institute of India (SII) has said the allegations in his legal notice are “malicious and misconceived”, and the firm will ask for damages in excess of Rs 100 crore for them.

The SII Chief Executive on Saturday indicated the company would apply to the regulator in two weeks for an emergency use authorisation (EUA) of the vaccine.

The volunteer fell sick 10 days after he was given a shot on October 1 in the clinical trial of